<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <title>GLP-1 Weight Loss Clinics in Palm Beach | Semaglutide & Tirzepatide</title>

  <meta name="description"
    content="Browse GLP-1 weight loss clinics in Palm Beach offering semaglutide, tirzepatide, and medically supervised programs across Palm Beach County." />

  <meta name="robots" content="index,follow" />

  <!-- Canonical -->
  <link rel="canonical" href="https://palmbeachglp1.com/" />

  <!-- Styles (explicit relative path + cache bust) -->
  <link rel="stylesheet" href="./styles.css?v=7" />

  <!-- Favicon -->
  <link rel="icon" href="./assets/favicon.ico" />

  <!-- Schema (sample placeholders) -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "ItemList",
    "name": "GLP-1 Weight Loss Clinics in Palm Beach",
    "description": "Directory of Palm Beach clinics offering semaglutide, tirzepatide, and medically supervised weight loss programs.",
    "url": "https://palmbeachglp1.com/",
    "numberOfItems": 3,
    "itemListElement": [
      { "@type": "LocalBusiness", "position": 1, "name": "Clinic Name", "areaServed": "West Palm Beach, FL", "url": "https://example.com" },
      { "@type": "LocalBusiness", "position": 2, "name": "Clinic Name", "areaServed": "Palm Beach Gardens, FL", "url": "https://example.com" },
      { "@type": "LocalBusiness", "position": 3, "name": "Clinic Name", "areaServed": "Boca Raton, FL", "url": "https://example.com" }
    ]
  }
  </script>
</head>

<body>

<a class="skip-link" href="#main">Skip to content</a>

<header class="header">
  <div class="container header-inner">
    <div class="brand">
      <a href="./index.html"><strong>PalmBeachGLP1</strong></a>
      <small class="muted">Local GLP-1 Clinic Directory</small>
    </div>

    <nav class="nav" aria-label="Primary">
      <a href="./index.html">Home</a>
      <a href="./listings.html">Clinics</a>
      <button class="share-btn" type="button" id="shareBtn" aria-label="Share this page" title="Share">
      <!-- simple share icon (SVG) -->
        <svg width="20" height="20" viewBox="0 0 24 24" aria-hidden="true" focusable="false">
        <path fill="currentColor" d="M18 16.08c-.76 0-1.44.3-1.96.77L8.91 12.7a2.5 2.5 0 0 0 0-1.39l7.02-4.11A2.99 2.99 0 1 0 14 5a3 3 0 0 0 .05.52L7.03 9.63a3 3 0 1 0 0 4.74l7.02 4.11c-.03.17-.05.34-.05.52a3 3 0 1 0 3-2.92Z"/>
        </svg>
      </button>
    </nav>
  </div>
</header>

<main id="main">

  <!-- INTRO -->
  <section class="section">
    <div class="container">

      <h1>GLP-1 Weight Loss Clinics in Palm Beach</h1>

      <p class="body-lg">
        GLP-1 medications such as semaglutide and tirzepatide are increasingly used in medically supervised
        weight-loss programs. This guide explains how these treatments work and helps you explore reputable
        providers across Palm Beach County.
      </p>

      <p class="body-lg">
        Clinics may offer structured programs including consultations, monitoring, and ongoing support.
        Understanding your options first can make comparing providers easier.
      </p>

      <!-- Large image below first paragraph -->
      <div class="feature-image">
        <img src="assets/glp1-consultation.jpg"
             alt="Doctor consulting with patient about medically supervised weight loss options">
        <p class="image-caption">
          Medical consultation discussing treatment options and supervised weight-loss care.
        </p>
      </div>

    </div>
  </section>

 <!-- HOW IT WORKS -->
<section class="section">
  <div class="container">
    <h2>How GLP-1 treatments work</h2>

    <p class="body-lg">
      GLP-1 medications belong to a class called <strong>GLP-1 receptor agonists</strong>. In simple terms,
      these medicines mimic a natural hormone released by the gut after eating that helps regulate appetite
      and blood sugar levels. By reinforcing signals of fullness and reducing hunger, they can help lower
      overall calorie intake when combined with lifestyle changes.
    </p>

    <p class="body-lg">
      One effect of GLP-1 medicines is that they slow <strong>gastric emptying</strong>, meaning food moves
      more gradually from the stomach into the small intestine. This can increase feelings of fullness after
      meals, but it also explains why some people experience nausea or digestive discomfort—especially when
      first starting treatment or increasing doses.
    </p>

    <p class="body-lg">
      Some newer medications, such as tirzepatide, act on both GLP-1 and another hormone receptor called
      <strong>GIP (glucose-dependent insulinotropic polypeptide)</strong>, a naturally occurring hormone
      involved in metabolic signaling. Because responses vary from person to person, treatment programs
      usually follow a gradual <strong>dose escalation (also called titration)</strong>, where the medication
      dose is increased step-by-step to improve tolerability while monitoring progress.
    </p>

    <p class="body-lg">
      Programs vary by clinic and may include consultations, follow-ups, nutrition guidance, and monitoring.
      Not every treatment is appropriate for every patient. A consultation with a licensed provider helps
      determine eligibility, expected outcomes, and how side effects should be managed.
    </p>

    <p class="sources">
      Sources:
      <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy (semaglutide) prescribing information</a>
      ·
      <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound (tirzepatide) prescribing information</a>
      ·
      <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists overview</a>
      ·
      <a href="https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730" target="_blank" rel="nofollow noopener">Mayo Clinic: semaglutide overview</a>
    </p>

  </div>
</section>


  <!-- EXPLORE (UPDATED: 2–3 paragraphs each + citations; only title is linked) -->
  <section class="section" id="explore">
    <div class="container">
      <h2>Explore treatment types</h2>
      <p class="muted">Start with the most common GLP-1 and medical weight-loss options.</p>

      <div class="service-list" role="list">

        <!-- SEMAGLUTIDE -->
        <div class="service-item" role="listitem">
          <a class="service-link" href="./listings.html#semaglutide">Semaglutide Programs</a>

          <p class="service-desc">
            Semaglutide is a medication in the GLP-1 receptor agonist class. GLP-1 is a hormone your body releases
            after eating; medicines in this class mimic that signal. In medically supervised weight-loss care,
            semaglutide is typically used alongside nutrition and activity changes as part of a structured plan.
          </p>
          <p class="service-desc">
            Many people experience reduced hunger and earlier fullness. GLP-1 medicines can also slow stomach
            emptying, which is one reason nausea or “feeling very full” may occur—especially early in treatment
            or after a dose increase.
          </p>
          <p class="service-desc">
            In real-world clinic programs, “semaglutide” usually includes more than a prescription: an intake visit,
            stepwise dose escalation to improve tolerability, and follow-ups to review side effects, progress,
            and next steps.
          </p>

          <p class="sources">
            Sources:
            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy (semaglutide) label</a>
            ·
            <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists</a>
            ·
            <a href="https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730" target="_blank" rel="nofollow noopener">Mayo Clinic: semaglutide</a>
          </p>
        </div>

        <!-- TIRZEPATIDE -->
        <div class="service-item" role="listitem">
          <a class="service-link" href="./listings.html#tirzepatide">Tirzepatide Options</a>

          <p class="service-desc">
            Tirzepatide is different from semaglutide in a key way: it activates two hormone receptors (GIP and GLP-1).
            The FDA labeling describes tirzepatide as a “GIP receptor and GLP-1 receptor agonist.”
            In weight management programs, clinics may offer it as an option depending on a patient’s clinical picture,
            prior medication experience, or provider protocol.
          </p>
          <p class="service-desc">
            Like GLP-1 medicines, tirzepatide is associated with appetite regulation and can affect digestion.
            Many programs use a gradual dose-increase plan to improve tolerability, with follow-ups to review side effects,
            progress, and whether adjustments are needed.
          </p>
          <p class="service-desc">
            If you’re comparing clinics, a useful differentiator is how they supervise the process: how often you check in,
            what symptom guidance is provided, and how quickly dose increases are paused or modified when side effects occur.
          </p>

          <p class="sources">
            Sources:
            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound (tirzepatide) label</a>
            ·
            <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists (mechanism & effects)</a>
          </p>
        </div>

        <!-- MEDICAL WEIGHT LOSS -->
        <div class="service-item" role="listitem">
          <a class="service-link" href="./listings.html#medical-weight-loss">Medical Weight Loss</a>

          <p class="service-desc">
            Medical weight loss is a broader category than GLP-1 medications alone. These are clinician-guided programs
            that may combine evaluation, nutrition counseling, activity planning, and behavior-change support. Some clinics
            include labs or other clinical measures depending on the patient and the program’s approach.
          </p>
          <p class="service-desc">
            If you’re early in the process, this category can be a strong starting point because it doesn’t assume a single
            medication path. Some programs focus on building a plan first and consider medications (including GLP-1 options)
            when it fits the clinical picture.
          </p>
          <p class="service-desc">
            When comparing clinics, look for clarity on what is included: intake, follow-ups, coaching, and any monitoring.
            Two “medical weight loss” programs can be very different in structure and support.
          </p>

          <p class="sources">
            Sources:
            <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists (overview & care context)</a>
          </p>
        </div>

        <!-- CONCIERGE WELLNESS -->
        <div class="service-item" role="listitem">
          <a class="service-link" href="./listings.html#concierge-wellness">Concierge Wellness</a>

          <p class="service-desc">
            Concierge wellness is usually a service model rather than a single treatment. These providers often emphasize
            more personalized care plans, longer appointments, and easier access to the care team. The experience may feel
            higher-touch compared with standard office visits.
          </p>
          <p class="service-desc">
            Concierge practices may offer GLP-1 pathways and/or broader wellness services (for example, more frequent check-ins
            or expanded lifestyle support). Because offerings can vary widely, this category is most useful when clinics clearly
            state what’s included and what is billed separately.
          </p>
          <p class="service-desc">
            If you prefer structured guidance, ask how follow-ups work and what support is provided between visits. The level of
            access and the scope of services are often the main differentiators here.
          </p>

          <p class="sources">
            Sources:
            <a href="https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730" target="_blank" rel="nofollow noopener">Mayo Clinic: semaglutide (patient counseling & safety)</a>
          </p>
        </div>

      </div>

    </div>
  </section>

    <!-- WHAT TO EXPECT + BEGINNER GUIDE (UPDATED: multi-paragraph sections + citations) -->
  <section class="section" id="what-to-expect">
    <div class="container">

      <h2>What to expect when starting a program</h2>

      <h3>Initial consult: medical history, goals, and eligibility</h3>
      <p class="body-lg">
        Most programs begin with an intake visit designed to understand your goals and determine whether a medication-based
        approach is appropriate. Expect a review of medical history, current medications, and prior weight-loss attempts.
        This is also when a clinician should discuss important safety considerations and what symptoms to report promptly.
      </p>
      <p class="body-lg">
        A high-quality consult also clarifies how the program works: how often follow-ups occur, how dose changes are managed,
        and what support is available between visits. That structure often matters as much as the medication choice.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment" target="_blank" rel="nofollow noopener">NIDDK (NIH): Treatment for overweight &amp; obesity</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy (semaglutide) label</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound (tirzepatide) label</a>
      </p>

      <h3>Dosing approach: gradual dose changes and what to watch</h3>
      <p class="body-lg">
        GLP-1 class medications are commonly started at a lower dose and increased over time (often called titration or dose
        escalation). This stepwise approach is used to improve tolerability, since gastrointestinal side effects can be more
        noticeable early on or after dose increases.
      </p>
      <p class="body-lg">
        Clinics differ in how they guide patients through this phase. Look for clear, practical instructions on what is common,
        what can be managed at home, and when to contact a clinician—especially for severe or persistent symptoms.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy (semaglutide) label (dosing/titration)</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound (tirzepatide) label (dosing/titration)</a>
        ·
        <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists (side effects &amp; care)</a>
      </p>

      <h3>Monitoring: follow-ups, vitals, and sometimes labs</h3>
      <p class="body-lg">
        Follow-ups are where “medically supervised” care becomes meaningful. Many clinics schedule check-ins to review weight
        change, appetite, side effects, hydration, and adherence, and to decide whether a dose change is appropriate.
      </p>
      <p class="body-lg">
        Some programs include vitals and labs depending on the patient and clinic protocol. If labs are used, ask which ones are
        checked and why—good clinics can explain their monitoring choices in plain language.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment" target="_blank" rel="nofollow noopener">NIDDK (NIH): Treatment for overweight &amp; obesity</a>
        ·
        <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists overview</a>
      </p>

      <h3>Support: nutrition guidance and lifestyle changes vary by provider</h3>
      <p class="body-lg">
        Medication can change appetite, but long-term results often depend on what you do with that change. Some clinics provide
        nutrition counseling, coaching, or structured behavior-change support; others primarily focus on prescribing and follow-ups.
      </p>
      <p class="body-lg">
        If you want more guidance, compare clinics based on what support is included (education, coaching touchpoints, written
        resources, or referral options). Different levels of support can be a better “fit” depending on what you need.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment" target="_blank" rel="nofollow noopener">NIDDK (NIH): Treatment for overweight &amp; obesity</a>
        ·
        <a href="https://www.cdc.gov/healthy-weight-growth/losing-weight/index.html" target="_blank" rel="nofollow noopener">CDC: Steps for losing weight (includes support)</a>
      </p>

      <h3>Costs: what varies and what to ask upfront</h3>
      <p class="body-lg">
        Costs can vary substantially because programs differ in what they bundle: intake visits, follow-ups, optional coaching,
        and any labs. Some clinics bill visits individually; others charge a program fee with defined inclusions.
      </p>
      <p class="body-lg">
        A simple approach is to ask for a breakdown for the first 1–3 months: what is included, what is optional, and what is
        billed separately. That makes it easier to compare clinics apples-to-apples.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.medicare.gov/health-drug-plans/part-d/what-drug-plans-cover" target="_blank" rel="nofollow noopener">Medicare.gov: What drug plans cover (formularies vary by plan)</a>
        ·
        <a href="https://www.cms.gov/medicare/coverage/prescription-drug-coverage" target="_blank" rel="nofollow noopener">CMS: Prescription drug coverage overview</a>
      </p>

      <h2>Common questions before starting</h2>
      <p class="body-lg">
        People often ask: “Do I need labs?” “How often are visits?” and “What happens if side effects occur?”
        Those questions are strongest when made specific. For example: “If I develop nausea, do you pause dose increases?”
        “How quickly can I get a follow-up if symptoms are significant?” and “Do you provide written guidance for managing common
        side effects?”
      </p>
      <p class="body-lg">
        Another common question is timeline: some people notice appetite changes early, while others notice effects more gradually
        across multiple doses. Clinics should set expectations that responses vary, and that dose titration and follow-ups are part
        of the process.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955" target="_blank" rel="nofollow noopener">Mayo Clinic: GLP-1 Q&amp;A</a>
        ·
        <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists</a>
      </p>

      <h2>Side effects and tolerance basics</h2>
      <p class="body-lg">
        The most commonly reported side effects for GLP-1–based medications are gastrointestinal—nausea, vomiting, diarrhea,
        constipation—and they can be more noticeable during dose escalation. This is one reason many programs titrate gradually
        and provide symptom-management guidance.
      </p>
      <p class="body-lg">
        It’s also important to know when to seek medical advice. Reputable sources advise contacting a clinician for severe,
        persistent, or unusual symptoms, and for symptoms that feel urgent. A clinic should be willing to explain what “common”
        looks like versus what should be evaluated promptly.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy (semaglutide) label (adverse reactions &amp; warnings)</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound (tirzepatide) label (adverse reactions &amp; warnings)</a>
        ·
        <a href="https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730" target="_blank" rel="nofollow noopener">Mayo Clinic: semaglutide overview</a>
      </p>

      <h2>Insurance vs self-pay</h2>
      <p class="body-lg">
        Some providers bill insurance for office visits (and sometimes labs), while other programs operate primarily on a self-pay
        model. Coverage depends on the plan, the diagnosis, and the specific medication prescribed, and it can vary widely.
      </p>
      <p class="body-lg">
        A practical way to compare is to ask clinics how they handle billing: what is billed to insurance (if anything), what is
        self-pay, and what costs are commonly encountered in the first few months.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.medicare.gov/health-drug-plans/part-d/what-drug-plans-cover" target="_blank" rel="nofollow noopener">Medicare.gov: Part D formularies vary by plan</a>
        ·
        <a href="https://www.cms.gov/medicare/coverage/prescription-drug-coverage/formulary-guidance" target="_blank" rel="nofollow noopener">CMS: Formulary guidance (plan drug lists)</a>
        ·
        <a href="https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/" target="_blank" rel="nofollow noopener">KFF: Medicaid coverage of GLP-1s (overview)</a>
      </p>

      <h2>Safety and eligibility basics</h2>
      <p class="body-lg">
        Not everyone is a candidate for these medications. Eligibility depends on medical history, other medications, and risk
        considerations discussed in prescribing information and clinical guidance. This is why a clinician-led consult matters.
      </p>
      <p class="body-lg">
        Your goal as a reader is not to self-diagnose—you’re preparing to choose a reputable provider and ask better questions.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity" target="_blank" rel="nofollow noopener">NIDDK (NIH): Prescription weight-loss medications (risks &amp; benefits)</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy label (contraindications &amp; warnings)</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound label (contraindications &amp; warnings)</a>
      </p>

      <h2>What “medically supervised” can mean</h2>
      <p class="body-lg">
        “Medically supervised” can range from telehealth-only prescribing with periodic check-ins to in-person clinics that include
        vitals, labs (when appropriate), and more frequent follow-up. Telehealth can be convenient; in-person care can offer more
        hands-on monitoring.
      </p>
      <p class="body-lg">
        The best fit often depends on preference and complexity. Your directory can help by noting whether clinics are telehealth,
        in-person, or hybrid, and what follow-up cadence they describe.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment" target="_blank" rel="nofollow noopener">NIDDK (NIH): Treatment options and care models</a>
        ·
        <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists (care context)</a>
      </p>

      <h2>Glossary</h2>
      <p class="body-lg">
        <strong>GLP-1 (glucagon-like peptide-1):</strong> A gut hormone involved in appetite and glucose regulation; GLP-1 medicines mimic its effects.
      </p>
      <p class="body-lg">
        <strong>GIP (glucose-dependent insulinotropic polypeptide):</strong> Another gut hormone receptor; tirzepatide activates both GIP and GLP-1 receptors.
      </p>
      <p class="body-lg">
        <strong>Dose escalation / titration:</strong> Gradual dose increases over time to improve tolerability.
        <strong>Maintenance dose:</strong> A longer-term dose level after titration, if tolerated and clinically appropriate.
      </p>
      <p class="sources">
        Sources:
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf" target="_blank" rel="nofollow noopener">FDA Wegovy label</a>
        ·
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf" target="_blank" rel="nofollow noopener">FDA Zepbound label</a>
        ·
        <a href="https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists" target="_blank" rel="nofollow noopener">Cleveland Clinic: GLP-1 agonists</a>
      </p>
    </div>
  </section>


  <!-- PROVIDERS (NOT “FEATURED”) -->
  <section class="section">
    <div class="container">

      <h2>Providers to start your search</h2>
      <p class="muted">A starting point for exploring local providers.</p>

      <div class="clinic-list">

        <article class="clinic">
          <h3>Clinic Name</h3>
          <p class="meta">West Palm Beach</p>
          <p class="clinic-desc">GLP-1 weight-loss programs with clinician supervision and follow-up care.</p>
          <a class="action-link" href="#" target="_blank" rel="nofollow noopener">Visit Website</a>
        </article>

        <article class="clinic">
          <h3>Clinic Name</h3>
          <p class="meta">Palm Beach Gardens</p>
          <p class="clinic-desc">Semaglutide and tirzepatide treatment options with ongoing monitoring.</p>
          <a class="action-link" href="#" target="_blank" rel="nofollow noopener">Visit Website</a>
        </article>

      </div>

      <p class="cta-row">
        <a class="action-link" href="./listings.html">See all clinics</a>
      </p>

    </div>
  </section>

</main>

<footer class="footer">
  <div class="container">
    <p class="muted">© <span id="year"></span> PalmBeachGLP1.com — Local directory resource.</p>
  </div>
</footer>

<script>
  document.getElementById("year").textContent = new Date().getFullYear();
</script>

<script>
document.addEventListener("DOMContentLoaded", function () {

  var btn = document.getElementById("shareBtn");
  if (!btn) return;

  btn.addEventListener("click", async function () {
    var url = window.location.href;

    if (navigator.share) {
      try {
        await navigator.share({
          title: document.title,
          url: url
        });
      } catch (e) {}
    }
  });

});
</script>


</body>
</html>
